Changes in serum acute phase proteins in ovarian cancer patients receiving cis-diamminedichloroplatinum (CDDP) infusion therapy.
Nine patients with adenocarcinoma of the ovary were given a number of courses of Cisplatin, by I.V. infusion. In four patients a complete clinical response was observed and these patients are disease-free one year after treatment. There was no clinical response in the remaining five patients who have subsequently died. Serial determinations of three acute-phase reactant proteins (alpha 1-acid glycoprotein, haptoglobin, alpha 1-antitrypsin) were performed before every infusion and after therapy. Constantly high or rising serum levels of haptoglobin and alpha 1-acid glycoprotein were associated with progression of the cancer, whereas in patients who were disease-free after therapy, these glycoproteins remained essentially in the normal range. The results suggest that serial measurements of haptoglobin and alpha 1-acid glycoprotein may have clinical value as aids in deciding the effectiveness of drug therapy in these patients.
D000209:Acute-Phase Proteins; D000230:Adenocarcinoma / Q000097:blood* / Q000188:drug therapy; D000328:Adult; D000368:Aged; D001798:Blood Proteins / Q000378:metabolism*; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D006242:Haptoglobins / Q000378:metabolism; D006801:Humans; D008875:Middle Aged; D009961:Orosomucoid / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy; D013997:Time Factors; D000515:alpha 1-Antitrypsin / Q000378:metabolism
D000209:Acute-Phase Proteins; D001798:Blood Proteins; D006242:Haptoglobins; D009961:Orosomucoid; D000515:alpha 1-Antitrypsin; D002945:Cisplatin